Pathogenicity of Cryptococcus neoformans VNI (ST 32) recovered from environmental and clinical isolates in Nigeria
- 7 Downloads
We present the comparative pathogenicity of Nigeria environmental and clinical Cryptococcus neoformans VNI (ST32) strains in an animal model. Isolates previously identified and confirmed in a different study, using matrix-assisted laser desorption ionization–time-of-flight mass spectrometry (MALDI–TOF MS) and multi-locus sequence typing (MLST) techniques, were inoculated into male mice weighing 26 ± 4.0 g. Postinfection survival time, tissue fungal burden, and histopathological changes were observed. Log–rank survival curve comparisons showed that there is a significant difference between clinical and control isolates and between environmental and control isolates. However, when intragroup and intergroup comparisons were made, no significant difference was observed. There was a significant difference when the brain fungal burden of mice infected with environmental isolate was compared with the kidney fungal burden. Tissues of the control group inoculated with PBS showed no evidence of lesions. The mouse group infected with clinical isolates showed a significant difference when the brain fungal burden was compared with the kidney fungal burden. No lesion was produced in the kidneys of mouse groups infected with environmental and positive control isolates. The evaluated pathogenicity indices in this study may suggest that both the environmental and clinical isolates of C. neoformans VNI exhibit similar pathogenicity potential.
KeywordsCryptococcus neoformans Pathogenicity Nigeria Fungal burden Clinical Environmental
We express our profound gratitude to our kind collaborators, Dr. Ferry Hagen and Prof. JF Meis, both of the Department of Medical Microbiology and Infectious Diseases, Wilhelmina Ziekenhuis, Nijmegen, The Netherlands, for the confirmation (using molecular tools) of the experimental cryptococcal strains used in this study.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. This article does not contain any studies with human participants performed by any of the authors.
- Bicanic T, Brouwer AE, Meintjes G, Rebe K, Limmathurotsakul D, Chierakul W, Teparrakkul P, Loyse A, White NJ, Wood R, Jaffar S, Harrison T (2009) Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures. AIDS 23(6):701–706PubMedGoogle Scholar
- Cianciolo RE, Rhodes JL, Haskins ME, Clubb FJ, Lees GE (2011) Renal failure associated with mucopolysaccharidosis type I in a cat from a MPSI research colony. Comp Med 61(5):44–444Google Scholar
- Clancy JC, Nguyen HM, Alandoerffer R, Cheng S, Kzkowski K, Richardson M, Graybill RJ (2006) Cryptococcus neoformans var. grubii isolates recovered from persons with AIDS demonstrate a wide range of virulence during murine meningoencephalitis that correlates with the expression of certain virulence factors. Microbiology 152:2247–2255CrossRefGoogle Scholar
- De Jesus M, Park CG, Su Y, Goldman DL, Steinman RM, Casadevall A (2008) Spleen deposition of Cryptococcus neoformans capsular glucuronoxylomannan in rodents occurs in red pulp macrophages and not marginal zone macrophages expressing the C – type lectin SIGN – RI. Med Mycol 46(2):62153–62162CrossRefGoogle Scholar
- Parikh V, Tucci V, Galwankar S (2013) Infections of the nervous system. Int J Crit Illn Inj Sci 3(1):82–97Google Scholar
- Perry C, Chung J-Y, Ylaya K, Choi CH, Simpson A, Matsumoto KT and Hewitt SM (2016) A buffered Alcohol – Based Fixative for Histomorphologic and Molecular Applications. Journal of Histochemistry and Cytochemistry, 64 (7): 425–440Google Scholar
- Pongmekin P, Chongtrakool P, Santanirand P, Kiertiburanakul S (2014) Clinical characteristics and mortality risk factors of cryptococcal infection among HIV-negative patients. J Med Assoc Thail 197(1):36–43Google Scholar
- Robertson EJ, Najjuka G, Rolfes MA, Akampurisa A, Jain N, Anantharanjit, von Hoherberg M, Tassieri M, Carlsson A, Meya DB, Harrison TS, Fries BC, Boulware DR, Bicanic T (2014) Cryptococcus neoformans ex vivo capsule size is associated with intracranial pressure and host immune response in HIV-associated cryptococcal meningitis. J Infect Dis 209:74–82CrossRefGoogle Scholar
- Silva EG, Baroni FA, Viani FC, Ruiz LS, Gandra RF, Auler ME, Dias AL, Gambale W, Paula CR (2006) Virulence profile of strains of Cryptococcus neoformans var. grubii evaluated by experimental infection in BALB/C mice and correlation with exoenzyme activity. J Med Microbiol 55:139–142CrossRefGoogle Scholar
- Velez N, Escandon P (2016) Distribution and association between environmental and clinical isolates of Cryptococcus neoformans in Bogota—Colombia, 2012–2015. Mem Inst Oswaldo Cruz 111(10):642–648Google Scholar
- Zhang B, Yu J, Liu L, Peng L, Chi F, Wu C, Jong A, Wang S, CaO H, Huang S (2015) Alpha 7 nicotinic acetylcholine receptor is required for blood/brain barrier injury-related CNS disorders caused by Cryptococcus neoformans and HIV-1 associated comorbidity factors. BMC Infect Dis 15:352CrossRefGoogle Scholar